Anti-Parainfluenza Viruses Pool ELISA (IgM)
Test instruction

ORDER NO.	ANTIBODIES AGAINST	IG-CLASS	SUBSTRATE	FORMAT
EI 2721-9601-1 M	Parainfluenza viruses, antigen pool of type 1 to 4	IgM	Ag-coated microplate wells	96 x 01 (96)

Principles of the test: The ELISA test kit provides a semiquantitative in vitro assay for human antibodies of the IgM class against Parainfluenza viruses of the types 1 to 4 in serum or plasma. The test kit contains microtiter strips each with 8 break-off reagent wells coated with with an antigen pool of Parainfluenza viruses types 1 to 4. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgM antibodies (also IgA and IgG) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgM (enzyme conjugate), which is capable of promoting a colour reaction.

Contents of the test kit:

Component	Colour	Format	Symbol
1. Microplate wells coated with antigens: 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use	---	12 x 8	STRIPS
2. Calibrator 200 RU/ml (IgM, human), ready for use	dark red	1 x 2.0 ml	CAL
3. Positive control (IgM, human), ready for use	blue	1 x 2.0 ml	POS CONTROL
4. Negative control (IgM, human), ready for use	green	1 x 2.0 ml	NEG CONTROL
5. Enzyme conjugate peroxidase-labelled anti-human IgM (goat), ready for use	red	1 x 12 ml	CONJUGATE
6. Sample buffer containing IgG/RF-Absorbent (Anti-human IgG antibody preparation obtained from goat), ready for use	green	1 x 100 ml	SAMPLEBUFFER
7. Wash buffer 10x concentrate	colourless	1 x 100 ml	WASHBUFFER 10x
8. Chromogen/substrate solution TMB/H_2O_2, ready for use	colourless	1 x 12 ml	SUBSTRATE
9. Stop solution 0.5 M sulphuric acid, ready for use	colourless	1 x 12 ml	STOP SOLUTION
10. Test instruction	---	1 booklet	
11 Protocol with target values	---	1 protocol	
LOT Lot	CE		storage temperature
IVD In vitro determination			unopened usable until

Storage and stability: The test kit has to be stored at a temperature between +2°C to +8°C. Do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

Waste disposal: Patient samples, calibrators, controls and incubated microplate strips shoud be handled as infectious waste. All reagents should be disposed of according to official regulations.

Preparation and stability of the reagents

Note: All reagents must be brought to room temperature (+18°C to +25°C) around 30 minutes before use. After first use, the reagents are stable until the indicated expiry date if stored at +2°C to +8°C and protected from contamination, unless stated otherwise below.

- **Coated wells:** Ready for use. Tear open the resealable protective wrapping of the microplate at the recesses above the grip seam. Do not open until the microplate has reached room temperature to prevent the individual strips from moistening. Immediately replace the remaining wells of a partly used microplate in the protective wrapping and tightly seal with the integrated grip seam (Do not remove the desiccant bag).
  Once the protective wrapping has been opened for the first time, the wells coated with antigens can be stored in a dry place and at a temperature between +2°C and +8°C for a minimum of 4 months.

- **Calibrator and controls:** Ready for use. The reagents must be mixed thoroughly before use.

- **Enzyme conjugate**: Ready for use. The enzyme conjugate must be mixed thoroughly before use.

- **Sample buffer**: Ready for use.

- **Wash buffer**: The wash buffer is a 10x concentrate. If crystallization occurs in the concentrated buffer, warm it to 37°C and mix well before diluting. The quantity required should be removed from the bottle using a clean pipette and diluted with deionized or distilled water (1 part reagent plus 9 parts distilled water).
  For example, for 1 microplate strip: 5 ml concentrate plus 45 ml water.
  The ready-to-use diluted wash buffer is stable for 1 month when stored at +2°C to +8°C and handled properly.

- **Chromogen/substrate solution**: Ready for use. Close the bottle immediately after use, as the contents are sensitive to light. The Chromogen/substrate solution must be clear on use. Do not use the solution if it is blue coloured.

- **Stop solution:** Ready for use.

Warning: The controls and calibrators used have tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2 using enzyme immunoassays and indirect immunofluorescence methods. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the toxic agent sodium azide. Avoid contact with the skin.

Preparation and stability of the patient samples

Sample material: Human serum or EDTA, heparin or citrate plasma.

Stability: Patient samples to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Introduction: Before a patient sample is tested for specific antibodies of the IgM class, antibodies of class IgG must be removed by ultracentrifugation, chromatography or immunoabsorption. This procedure must be carried out in order to prevent any rheumatoid factors from reacting with specifically bound IgG, which would lead to false positive IgM test results, and to prevent specific IgG displacing IgM from the antigen, which would lead to false IgM negative test results.

Functional principle: The sample buffer (green coloured!) contains an anti-human antibody preparation from goat. IgG from a serum sample is bound with high specificity by these antibodies and precipitated. If the sample also contains rheumatoid factors, these will be absorbed by the IgG/anti-human IgG complex.

Separation properties:
- All IgG subclasses are bound and precipitated by the anti-human IgG antibodies.
- Human serum IgG in concentrations of up to 15 mg per ml are removed (average serum IgG concentration in adults: 12 mg per ml).
- Rheumatoid factors are also removed.
- The recovery rate of the IgM fraction is almost 100%.

Performance: The **patient samples** for analysis are diluted **1:101** with sample buffer. For example, add 10 µl serum to 1.0 ml sample buffer and mix well. Incubate the mixture for at least **10 minutes** at room temperature. Subsequently, it can be pipetted into the microplate wells according to the pipetting protocol.

Notes:
- Antibodies of the class IgG should not be analyzed with this mixture.
- It is possible to check the efficacy of the IgG/RF absorbent for an individual patient sample by performing an IgG test in parallel to the IgM test using the mixture. If the IgG test is negative, the IgM result can be considered as reliable.
- The calibrator and controls containing IgM antibodies are pre-diluted and ready for use, do not dilute them.

Incubation

Sample incubation:
(1. step)

Transfer 100 µl calibrator, positive and negative controls or diluted patient samples into the individual microplate wells according to the pipetting protocol. Incubate for **30 minutes** at room temperature (+18°C to +25°C).

Washing:

Manual: Empty the wells and subsequently wash 3 times using 300 µl of working strength wash buffer for each wash.
Automatic: Wash reagent wells 3 times with 400 µl working strength wash buffer (program setting: e.g. TECAN Columbus Washer "Overflow Modus").

Leave the wash buffer in each well for 30 to 60 seconds per washing cycle, then empty the wells. After washing (manual and automated tests), thoroughly dispose of all liquid from the microplate by tapping it on absorbent paper with the openings facing downwards to remove all residual wash buffer.

Note: Residual liquid (> 10 µl) remaining in the reagent wells after washing can interfere with the substrate and lead to falsely low extinction values. Insufficient washing (e.g., less than 3 wash cycles, too small wash buffer volumes, or too short reaction times) can lead to falsely high extinction values.
Free positions on the microplate strip should be filled with blank wells of the same plate format as that of the parameter to be investigated.

Conjugate incubation:
(2. step)

Pipette 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgM) into each of the microplate wells. Incubate for **30 minutes** at room temperature (+18°C bis 25°C).

Washing:

Empty the wells. Wash as described above.

Substrate incubation:
(3. step)

Pipette 100 µl of chromogen/substrate solution into each of the microplate wells. Incubate for **15 minutes** at room temperature (+18°C bis 25°C) (protect from direct sunlight).

Stopping the reaction:

Pipette 100 µl of stop solution into each of the microplate wells in the same order and at the same speed as the chromogen/substrate solution was introduced.

Measurement:

Photometric measurement of the colour intensity should be made at a wavelength of 450 nm and a reference wavelength of between 620 nm and 650 nm **within 30 minutes of adding the stop solution.** Prior to measuring, slightly shake the microplate to ensure a homogeneous distribution of the solution.

EUROIMMUN

Medizinische
Labordiagnostika
AG

Pipetting protocol

	1	2	3	4	5	6	7	8	9	10	11	12
A	C	P 6	P 14	P 22								
B	pos.	P 7	P 15	P 23								
C	neg.	P 8	P 16	P 24								
D	P 1	P 9	P 17									
E	P 2	P 10	P 18									
F	P 3	P 11	P 19									
G	P 4	P 12	P 20									
H	P 5	P 13	P 21									

The above pipetting protocol is an example of the semiquantitative analysis of antibodies in 24 patient samples (P 1 to P 24).

Calibrator (C), positive (pos.) and negative (neg.) control as well as the patient samples have been incubated in one well each. The reliability of the ELISA test can be improved by duplicate determinations of each sample.
The wells can be broken off individually from the strips. This makes it possible to adjust the number of test substrates used to the number of samples to be examined and minimizes reagent wastage.
Both positive and negative controls serve as internal controls for the reliability of the test procedure. They should be assayed with each test run.

Calculation of results

The extinction value of the calibrator defines the upper limit of the reference range of non-infected persons (**cut-off**) recommended by EUROIMMUN. Values above the indicated cut-off are to be considered as positive, those below as negative.

Semiquantitative: Results can be evaluated semiquantitatively by calculating a ratio of the extinction value of the control or patient sample over the extinction value of calibrator. Use the following formula to calculate the ratio:

$$\frac{\textbf{Extinction of the control or patient sample}}{\textbf{Extinction of calibrator}} = \textbf{Ratio}$$

EUROIMMUN recommends interpreting results as follows:

Ratio <0.8: negative
Ratio ≥0.8 to <1.1 borderline
Ratio ≥1.1: positive

In cases of borderline test results, an additional patient sample should be taken 7 days later and re-tested in parallel with the first patient sample. The results of both samples allow proper evaluation of titer changes.

For duplicate determinations the mean of the two values should be taken. If the two values deviate substantially from one another the sample should be retested.

For diagnosis, the clinical symptoms of the patient should always be taken into account alongside the serological results.

Test characteristics

Calibration: As no international reference serum exists for antibodies against Parainfluenza viruses, results are provided in the form of ratios which are a relative measure for the concentration of antibodies.

For every group of tests performed, the extinction values of the calibrator and the ratios of the positive and negative controls must lie within the limits stated for the relevant test kit lot. A protocol containing these target values is included. If the values specified for the controls are not achieved, the test results may be inaccurate and the test should be repeated.

The activity of the enzyme used is temperature-dependent and the extinction values may vary if a thermostat is not used. The higher the room temperature during substrate incubation, the greater will be the extinction values. Corresponding variations apply also to the incubation times. However, the calibrators are subject to the same influences, with the result that such variations will be largely compensated in the calculation of the result.

Antigen: The antigen source is provided by inactivated cell lysates of Vero cells infected with Parainfluenza viruses.

Detection limit: The detection limit is defined as a value of three times the standard deviation of an analyte-free sample and is the smallest detectable antibody titer. The detection limit of the Anti-Parainfluenza Viruses Pool ELISA (IgM) is ratio 0.08.

Cross reactivity: This ELISA showed no cross reactivity.

Interference: Haemolytic, lipaemic and icteric samples showed no influence at the result up to a concentration of 10 mg/ml for hemoglobin, 20 mg/ml for triglycerides and 0.4 mg/ml for bilirubin in this ELISA.

Reproducibility: The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation (CV) using 3 sera with values at different points on the calibration curve. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on 4 determinations performed on 6 different days.

Intra-Assay-Variation, n = 20		
Serum	Mean value (Ratio)	VK (%)
1	1.3	3.4
2	2.5	6.6
3	5.6	7.4

Inter-Assay-Variation, n = 4 x 6		
Serum	Mean value (Ratio)	VK (%)
1	1.2	4.1
2	2.3	4.8
3	4.9	4.8

Reference range: The levels of the anti-Parainfluenza viruses antibodies (IgM) were analyzed with this EUROIMMUN ELISA in a panel of 300 healthy blood donors. With a cut-off ratio of 1.0, 2.4% of the blood donors were anti-Parainfluenza viruses positive (IgM).

Clinical significance

Parainfluenza viruses can be found worldwide. In the case of children and babies, they are responsible for about 35 % of all acute infections of the respiratory tract. In serious cases, they can give rise to pseudo-croup. With adults, infections with parainfluenza virus lead to diseases in the upper respiratory tract, mostly accompanied by fever. Parainfluenza viruses can occur endemically, mainly between late autumn and spring. They are transmitted via aerosols.

Antibodies against the individual parainfluenza virus types frequently show cross reactions between each another.

Literature references

1. Döller G. **Parainfluenzaviren.** in: Porstmann T. Virusdiagnostik. Blackwell Wissenschafts-Verlag, Berlin, Wien S. 363-377 (1996).

2. Frankova V, Holubova J, Grubhoffer L, Kasova V. **Contribution to laboratory diagnosis of mumps and parainfluenza.** Acta Virol 32: 503-514 (1988).

3. Fedova D, Novotny J, Kubinova I. **Serological diagnosis of parainfluenza virus infections: verification of the sensitivity and specificity of the haemagglutination-inhibition (HI), complement-fixation (CF), immunofluorescence (IFA) tests and enzyme immunoassay (ELISA).** Acta Virol 36: 304-312 (1992).

4. Julkunen I. **Serological diagnosis of parainfluenza virus infections by enzyme immunoassay with special emphasis on purity of viral antigens.** J Med Virol 14: 177-187 (1984).

5. Glikmann G, Mordhorst CH. **Serological diagnosis of mumps and parainfluenza type-1 virus infections by enzyme immunoassay, with a comparison of two different approaches for detection of mumps IgG antibodies.** Acta Pathol Microbiol Immunol Scand 94: 157-166 (1986).

6. Ukkonen P, Vaisanen O, Penttinen K. **Enzyme-linked immunosorbent assay for mumps and parainfluenza type 1 immunoglobulin G and immunoglobulin M antibodies.** J Clin Microbiol 11: 319-323 (1980).

7. van der Logt JT, van Loon AM, Heessen FW, van der Veen J. **Diagnosis of parainfluenza virus infection in children and older patients by detection of specific IgM antibody.** J Med Virol 16: 191-199 (1985).

8. Brinker JP, Doern GV. **A comparison of commercially available monoclonal antibodies for direct and indirect immunofluorescence culture confirmation and direct detection of parainfluenza viruses.** Diagn Microbiol Infect Dis15: 669-672 (1992).

9. Wong DT, Welliver RC, Riddlesberger KR, Sun MS, Ogra PL. **Rapid diagnosis of parainfluenza virus infection in children.** J Clin Microbiol 16: 164-167 (1982).